Vialox Peptide (Topical)

Buy Vialox Peptide: The Venom-Inspired Topical Alternative for Expression Lines

Vialox Peptide, scientifically known as Pentapeptide-3, is a synthetic peptide that has garnered significant attention in dermatological research for its unique, non-invasive approach to managing dynamic wrinkles.

With the amino acid sequence Gly-Pro-Arg-Pro-Ala-NH₂, this pentapeptide is a biomimetic fragment of the neurotoxin waglerin-1, originally derived from the venom of the temple viper (Tropidolaemus wagleri). By mimicking the muscle-relaxing effects of neurotoxins, Vialox offers a needle-free alternative for addressing expression lines, positioning it as a valuable compound in the development of advanced topical formulations.

Vialox Peptide

Molecular Foundation and Design

Vialox Peptide is a synthetic pentapeptide with a molecular formula of C₂₁H₃₇N₉O₅ and a molecular weight of approximately 495.6 g/mol. Its sequence—Glycine, Proline, Arginine, Proline, and Alanine—is engineered to interact with specific receptors at the neuromuscular junction.

The synthesis is typically achieved through solid-phase peptide synthesis (SPPS), ensuring high purity (typically ≥95% to ≥98% by HPLC) and batch-to-batch consistency. Originally trademarked by Pentapharm AG (now DSM-Firmenich), Vialox is classified among neurotransmitter-inhibiting cosmeceutical peptides.

Mechanism of Action: A Postsynaptic Neuromuscular Blocker

Vialox Peptide operates through a distinct and well-defined mechanism at the neuromuscular junction. It functions as a competitive antagonist at muscle-type nicotinic acetylcholine receptors (nAChRs) on the postsynaptic membrane.

By binding to these receptors, Vialox obstructs acetylcholine from attaching to its sites, effectively blocking the transmission of nerve impulses. This prevents the sodium ion influx required for muscle fiber depolarization, thereby inhibiting muscle contraction.

The result is a significant and rapid reduction in muscle contraction frequency. In vitro studies demonstrate that Vialox Peptide can reduce muscle contractions by up to 71% within one minute of application, with 58% of muscle fibers remaining immotile two hours later. This action directly targets the formation of dynamic expression wrinkles—those caused by repetitive facial movements like frowning or squinting.

Anti-Aging Benefits and Clinical Potential Of Vialox Peptide

Vialox Peptide primary application lies in its ability to smooth expression lines and improve skin texture without the need for injections. As a topical alternative to botulinum toxin, it is often used in serums, creams, and ampoules designed for intensive anti-wrinkle care.

· Rapid and Cumulative Efficacy: In one clinical study, Pentapeptide 3 used twice daily for 28 days resulted in a nearly 50% reduction in wrinkle depth and roughness. This demonstrates both immediate smoothing effects and cumulative benefits over time.

· Synergistic Formulations: Vialox Peptide postsynaptic mechanism is mechanistically complementary to presynaptic inhibitors like Argireline (which inhibits SNARE complex formation) and opioid receptor agonists like Leuphasyl. This allows for three-mechanism “botox-like” formulations that target muscle contraction at multiple points, potentially enhancing efficacy.

· Safety Profile: In silico ADME and toxicity predictions suggest favorable pharmacokinetic and safety profiles. Furthermore, in vitro studies have shown no cytotoxicity on HaCaT cells (a human keratinocyte cell line) at concentrations up to 1 mg/mL, supporting its promise as a safe, noninvasive dermocosmetic agent.

Expanding Research Horizons

Beyond its established role in cosmetics, recent research is exploring Vialox’s potential in other areas. A 2025 integrative study investigated its anti-aging activity by targeting matrix metalloproteinases (MMPs) and Sirtuin-1 (SIRT-1), revealing that Vialox preferentially targets SIRT-1, a key regulator of cellular longevity.

More intriguingly, emerging research suggests that Vialox and related pentapeptides may show promising anticancer activity against specific cancer cell lines, with potential for targeted therapy development against EGFR and PI3K pathways. These findings highlight Vialox’s versatility beyond dermatological applications.

Quality and Research Use

Vialox is supplied as a lyophilized powder, stable at pH 4.5–7.5. A Certificate of Analysis (CoA), MS analysis, and HPLC purity report are typically provided with every batch to ensure quality and reproducibility.